

## IMPORTANT NOTICE

NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO U.S. PERSONS

**IMPORTANT: You must read the following disclaimer before continuing.** The following disclaimer applies to the attached preliminary pricing supplement. You are advised to read this disclaimer carefully before accessing, reading or making any other use of the attached preliminary pricing supplement. In accessing the attached preliminary pricing supplement, you agree to be bound by the following terms and conditions, including any modifications to them from time to time, each time you receive any information from us as a result of such access.

**Confirmation of Your Representation:** In order to be eligible to view the attached preliminary pricing supplement or make an investment decision with respect to the securities, investors must not be (i) a U.S. person (within the meaning of Regulation S under the Securities Act (as defined below)) or (ii) located within the United States ("U.S."). The attached preliminary pricing supplement is being sent at your request and by accepting the e-mail and accessing the attached preliminary pricing supplement, you shall be deemed to have represented to us (1) that you are not resident in the United States nor a U.S. person, as defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act") nor are you acting on behalf of a U.S. person, the electronic mail address that you gave us and to which this email has been delivered is not located in the U.S. and, to the extent you purchase the securities described in the attached preliminary pricing supplement, you will be doing so pursuant to Regulation S under the Securities Act, and (2) that you consent to delivery of the attached preliminary pricing supplement and any amendments or supplements thereto by electronic transmission. By accepting this document, if you are an investor in Singapore, you (A) represent and warrant that you are either an institutional investor (as defined in Section 4A of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA")) pursuant to Section 274 of the SFA, a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or a person to whom an offer is being made pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275 of the SFA and (where applicable) Regulation 3 of the Securities and Futures (Classes of Investors) Regulations 2018, and (B) agree to be bound by the limitations and restrictions described therein. Any reference to the "SFA" is a reference to the Securities and Futures Act, Chapter 289 of Singapore and a reference to any term as defined in the SFA or any provision in the SFA is a reference to that term or provision as modified or amended from time to time including by such of its subsidiary legislation as may be applicable at the relevant time.

The attached document has been made available to you in electronic form. You are reminded that documents or information transmitted via this medium may be altered or changed during the process of transmission and consequently none of Thomson Medical Group Limited, DBS Bank Ltd., Maybank Kim Eng Securities Pte. Ltd., Standard Chartered Bank (Singapore) Limited, or any person who controls any of them nor any of their respective directors, officers, employees, agents, representatives or affiliates accepts any liability or responsibility whatsoever in respect of any discrepancies between the document distributed to you in electronic format and the hard copy version.

**Restrictions:** The attached document is being furnished in connection with an offering of securities exempt from registration under the Securities Act solely for the purpose of enabling a prospective investor to consider the purchase of the securities described therein.

***NOTHING IN THIS ELECTRONIC TRANSMISSION CONSTITUTES AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DO SO. THE SECURITIES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE SECURITIES ACT, OR THE SECURITIES LAWS OF ANY STATE OF THE U.S. OR OTHER JURISDICTION AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE U.S. OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT), EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE OR LOCAL SECURITIES LAWS.***

Except with respect to eligible investors in jurisdictions where such offer is permitted by law, nothing in this electronic transmission constitutes an offer or an invitation by or on behalf of Thomson Medical Group Limited, DBS Bank Ltd., Maybank Kim Eng Securities Pte. Ltd., or Standard Chartered Bank (Singapore) Limited to subscribe for or purchase any of the securities described therein, and access has been limited so that it shall not constitute in the United States or elsewhere a general solicitation or general advertising (as those terms are used in Regulation D under the Securities Act) or directed selling efforts (as defined in Regulation S under the Securities Act).

The attached preliminary pricing supplement or any materials relating to the offering do not constitute, and may not be used in connection with, an offer or solicitation in any place where offers or solicitations are not permitted by law. If a jurisdiction requires that the offering be made by a licensed broker or dealer and the dealers or any affiliate of the dealers is a licensed broker or dealer in that jurisdiction, the offering shall be deemed to be made by the dealers or such affiliate on behalf of Thomson Medical Group Limited in such jurisdiction. The attached preliminary pricing supplement may only be communicated to persons in the United Kingdom in circumstances where section 21(1) of the Financial Services and Markets Act 2000 does not apply.

You are reminded that you have accessed the attached preliminary pricing supplement on the basis that you are a person into whose possession this preliminary pricing supplement may be lawfully delivered in accordance with the laws of the jurisdiction in which you are located and you may not nor are you authorised to deliver this document, electronically or otherwise, to any other person. **If you have gained access to this transmission contrary to the foregoing restrictions,**

**you will be unable to purchase any of the securities described therein.**

**Actions that You May Not Take:** If you receive this document by e-mail, you should not reply by e-mail, and you may not purchase any securities by doing so. Any reply e-mail communications, including those you generate by using the "Reply" function on your e-mail software, will be ignored or rejected.

**YOU ARE NOT AUTHORISED AND YOU MAY NOT FORWARD OR DELIVER THE ATTACHED PRELIMINARY PRICING SUPPLEMENT, ELECTRONICALLY OR OTHERWISE, TO ANY OTHER PERSON OR REPRODUCE SUCH PRELIMINARY PRICING SUPPLEMENT IN ANY MANNER WHATSOEVER. ANY FORWARDING, DISTRIBUTION OR REPRODUCTION OF THIS DOCUMENT AND THE ATTACHED PRELIMINARY PRICING SUPPLEMENT IN WHOLE OR IN PART IS UNAUTHORISED. FAILURE TO COMPLY WITH THIS DIRECTIVE MAY RESULT IN A VIOLATION OF THE SECURITIES ACT OR THE APPLICABLE LAWS OF OTHER JURISDICTIONS.**

**You are responsible for protecting against viruses and other destructive items.** If you receive this document by e-mail, your use of this e-mail is at your own risk and it is your responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature.

SUBJECT TO AMENDMENT AND COMPLETION  
PRELIMINARY PRICING SUPPLEMENT DATED 20 JANUARY 2020

Pricing Supplement



THOMSON MEDICAL GROUP LIMITED  
(Incorporated with limited liability in Singapore)

S\$500,000,000  
Multicurrency Debt Issuance Programme

SERIES NO: 002  
TRANCHE NO: 001

S\$[●] [●] per cent. Notes Due 2025  
Issue Price: 100 per cent.

DBS Bank Ltd.  
Maybank Kim Eng Securities Pte. Ltd.  
Standard Chartered Bank (Singapore) Limited

Principal Paying Agent  
Deutsche Bank AG, Singapore Branch  
One Raffles Quay, #16-00, South Tower, Singapore 048583

The date of this Pricing Supplement is [●].

The information in this Preliminary Pricing Supplement is not complete and may be changed. This Preliminary Pricing Supplement is not an offer to sell nor is it an offer to buy securities in any jurisdiction where such offer or sale is not permitted or to any person or entity to whom it is unlawful to make an offer or sale. The definitive terms of the transaction described herein will be described in the final form Pricing Supplement. Investors should not subscribe for any securities referred to in this Preliminary Pricing Supplement except on the basis of information contained in the combination of the final form Pricing Supplement and the Information Memorandum referred to herein.

This Pricing Supplement relates to the Tranche of Notes referred to above.

This Pricing Supplement, under which the Notes described herein (the “**Notes**”) are issued, is supplemental to, and should be read in conjunction with, the Information Memorandum dated 28 June 2019 (as revised, supplemented, amended, updated or replaced from time to time, the “**Information Memorandum**”) issued in relation to the S\$500,000,000 Multicurrency Debt Issuance Programme of Thomson Medical Group Limited (the “**Issuer**”). Terms defined in the Information Memorandum have the same meaning in this Pricing Supplement. The Notes will be issued on the terms of this Pricing Supplement read together with the Information Memorandum. The Issuer accepts responsibility for the information contained in this Pricing Supplement which, when read together with the Information Memorandum, contains all information that is material in the context of the issue and offering of the Notes.

This Pricing Supplement does not constitute, and may not be used for the purposes of, an offer or solicitation by anyone in any jurisdiction in which such offer or solicitation is not authorised or to any person to whom it is unlawful to make such offer or solicitation, and no action is being taken to permit an offering of the Notes or the distribution of this Pricing Supplement in any jurisdiction where such action is required.

Where interest, discount income, prepayment fee, redemption premium or break cost is derived from any of the Notes by any person who is not resident in Singapore and who carries on any operations in Singapore through a permanent establishment in Singapore, the tax exemption available for qualifying debt securities (subject to certain conditions) under the Income Tax Act, Chapter 134 of Singapore (the “**Income Tax Act**”) shall not apply if such person acquires such Notes using the funds and profits of such person’s operations through a permanent establishment in Singapore. Any person whose interest, discount income, prepayment fee, redemption premium or break cost derived from the Notes is not exempt from tax (including for the reasons described above) shall include such income in a return of income made under the Income Tax Act.

There has been no material adverse change, or any development which is likely to lead to a material adverse change, in the financial condition, business, assets or results of operations of the Issuer or the Group, taken as a whole since 30 September 2019.

**Notification under Section 309B of the Securities and Futures Act, Chapter 289 of Singapore:** The Notes are prescribed capital markets products (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).

**PRIIPs REGULATION - PROHIBITION OF SALES TO EEA RETAIL INVESTORS** – The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area (“**EEA**”). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of MiFID II; or (ii) a customer within the meaning of Directive 2002/92/EC (as amended or superseded, the “**Insurance Mediation Directive**”), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Directive 2003/71/EC (as amended or superseded, the “**Prospectus Directive**”). Consequently no key information document required by Regulation (EU) No 1286/2014 (as amended, the “**PRIIPs Regulation**”) for offering or selling the Notes or otherwise making them available to retail

investors in the EEA has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation.

**Thomson Medical Group Limited**

Signed: \_\_\_\_\_  
Director

The terms of the Notes and additional provisions relating to their issue are as follows:

- |     |   |  |
|-----|---|--|
| 1.  | Series No.:   | 002  |
| 2.  | Tranche No.:  | 001  |
| 3.  | Currency:   | Singapore Dollars  |
| 4.  | Principal Amount of Series:                                 | S\$[●]   |
| 5.  | Principal Amount of Tranche:                                | S\$[●]   |
| 6.  | Denomination Amount:  | S\$250,000   |
| 7.  | Calculation Amount (if different from Denomination Amount): | Not Applicable   |
| 8.  | Issue Date:   | [●] 2020   |
| 9.  | Redemption Amount (including early redemption):             | Denomination Amount  |
| 10. | Interest Basis:   | Fixed Rate   |
| 11. | Interest Commencement Date:                                 | [●] 2020   |
| 12. | Security:   | The obligations of the Issuer to pay any sum which is payable by it under the Notes are secured by a charge over interest service reserve accounts opened and maintained by the Issuer with Malayan Banking Berhad, Singapore Branch and into which moneys in an amount not less than S\$[●] (which is approximately equal to six months' interest payable on the Notes) are deposited and maintained in accordance with an Account Charge entered into or to be entered into between (1) the Issuer and (2) DB International Trust (Singapore) Limited as security trustee. |
| 13. | <b>Fixed Rate Note</b>                                      |  |
|     | (a) Maturity Date:  | [●] 2025   |
|     | (b) Day Count Fraction:                                     | Actual/365 (Fixed)   |

(c)	Interest Payment Date(s):	Interest on the Notes will be payable semi-annually in arrear on the dates falling on [●] and [●] in each year, commencing on [●]
(d)	Initial Broken Amount:	Not Applicable
(e)	Final Broken Amount:	Not Applicable
(f)	Interest Rate:	[●] per cent. per annum
14.	<b>Floating Rate Note</b>	Not Applicable
15.	<b>Variable Rate Note</b>	Not Applicable
16.	<b>Hybrid Note</b>	Not Applicable
17.	<b>Zero Coupon Note</b>	Not Applicable
18.	Issuer's Redemption Option	No
	Issuer's Redemption Option Period (Condition 6(d)):	Not Applicable
19.	Noteholders' Redemption Option	No
	Noteholders' Redemption Option Period (Condition 6(e)):	Not Applicable
20.	Issuer's Purchase Option	No
	Issuer's Purchase Option Period (Condition 6(b)):	Not Applicable
21.	Noteholders' VRN Purchase Option	No
	Noteholders' VRN Purchase Option Period (Condition 6(c)(i)):	Not Applicable
22.	Noteholders' Purchase Option	No
	Noteholders' Purchase Option Period (Condition 6(c)(ii)):	Not Applicable
23.	Redemption for Taxation Reasons: (Condition 6(f)):	Yes
24.	Redemption in the case of Minimal Outstanding Amount: (Condition 6(h)):	Yes
25.	Notes to be represented on issue by:	Bearer Permanent Global Security



26.	Talons for future Coupons to be attached to Definitive Notes (and dates on which such Talons mature:	No
27.	Applicable TEFRA exemption:	C Rules
28.	Listing:	Singapore Exchange Securities Trading Limited
29.	ISIN Code:	[•]
30.	Common Code:	[•]
31.	Clearing System(s):	The Central Depository (Pte) Limited
32.	Depository:	The Central Depository (Pte) Limited
33.	Delivery:	Delivery free of payment
34.	Method of issue of Notes:	Syndicated Issue
35.	The following Dealer(s) are Subscribing the Notes:	DBS Bank Ltd., Maybank Kim Eng Securities Pte. Ltd. and Standard Chartered Bank (Singapore) Limited
36.	Stabilising Manager(s) (if any):	Not Applicable
37.	Prohibition of Sales to EEA Retail Investors:	Not Applicable
38.	Paying Agent:	Principal Paying Agent
39.	The aggregate principal amount of Notes issued has been translated in Singapore dollars at the rate of [•] producing a sum of (for Notes not denominated in Singapore dollars):	Not Applicable
40.	Account Charge:	Applicable [•] 2020
41.	Relevant Interest Service Reserve Account:	Applicable
42.	Relevant Account Bank:	Malayan Banking Berhad, Singapore Branch
43.	Use of Proceeds:	The net proceeds arising from the issue of the Notes (after deducting issue expenses) will be used for the

refinancing of certain existing loan facilities

44. Private Bank Rebate/Commission:

Applicable. Private banking selling commission of 0.20 per cent. of the aggregate principal amount of the Notes allocated to private bank investors

45. Other terms:

Please refer to the Appendix of this Pricing Supplement

Details of any additions or variations to the terms and conditions of the Notes as set out in the Information Memorandum:

Not Applicable

Any additions or variations to the selling restrictions:

Not Applicable

## Appendix


- The section "Board of Directors" appearing on page 17 of the Information Memorandum shall be deleted in its entirety and substituted thereof for the following:

"Board of Directors : Ng Ser Miang  
Wilson Sam  
Heng Kim Chuan Freddie  
Lim Wee Kiat  
Ong Pang Liang  
Lam Lee G"

- The section "Corporate Structure" appearing on page 107 of the Information Memorandum shall be deleted in its entirety and substituted thereof for the following:

"

THOMSON MEDICAL GROUP LIMITED AND ITS SUBSIDIARIES  
CORPORATE STRUCTURE



"

- The section "(b) Experienced senior management team with proven track record" appearing on page 119 of the Information Memorandum shall be deleted in its entirety and substituted thereof for the following:

**"(b) Experienced senior management team with proven track record**

The senior management team of the Issuer, led by the directors, has extensive experience in the healthcare space in Singapore and Malaysia. The members of the Issuer's board of directors possess extensive industry experience and are instrumental to continuing the successful operations and growth of the Group in the region.

The leadership teams in both Singapore and Malaysia comprise strong and highly experienced industry professionals and will be led by Dr Wong Chiang Yin. Dr Wong will be appointed the Group Chief Executive Officer and Executive Director of the Issuer with effect from 1 February 2020, following which Dr Wong will be part of the senior management team in Singapore.

The senior management team in Singapore and Malaysia currently comprises Mr Wilson Sam, Ms Mega Shuen, Mr Tan Zing Yuen, Ms Wan Nadiyah Binti Wan Mohd Abdullah Yaakob, and Mr Wong Yu Chee. Please refer to the section entitled "Senior Management" on pages 131 and 132 of this Information Memorandum for further information on the senior management team."

4. The references to "Mr Quek Hong Sheng Roy" under the sub-section entitled "Directors" appearing on page 128 of the Information Memorandum shall be deleted in its entirety.
5. The write-up on "Mr Quek Hong Sheng Roy" under the sub-section entitled "Directors" appearing on pages 128 and 129 of the Information Memorandum shall be deleted in its entirety.
6. The references to "Mr Quek Hong Sheng Roy" under the sub-section entitled "Senior Management" appearing on page 131 of the Information Memorandum shall be deleted in its entirety.
7. The write-up on "Mr Quek Hong Sheng Roy" under the sub-section entitled "Senior Management" appearing on page 131 of the Information Memorandum shall be deleted in its entirety.
8. The following section titled "Recent Developments" shall be inserted at the end of the section titled "The Issuer" on page 132 of the Information Memorandum:

## **"9. RECENT DEVELOPMENTS**

### **Issuance of Notes**

On 18 July 2019, the Issuer issued S\$225 million 4.8% 3-year medium term notes due 2022 under the Programme that was established on 28 June 2019. The net proceeds arising from the issuance of the Notes (after deducting issue expenses) were used to finance the Group's existing borrowings. The Notes are secured by a charge over an interest service reserve account in which the Issuer maintains an interest reserve amount equivalent to six months' interest on the Notes.

### **Change in Directors and Management**

Mr Quek Hong Sheng Roy stepped down as the Executive Director and Group Chief Executive Officer of the Issuer with effect from 16 September 2019 and remained as a Non-Executive Director until 31 December 2019 where he stepped down as Non-Executive Director of the Issuer.

The Board appointed Dr Wong Chiang Yin as special advisor to the Issuer on 6 September 2019. Dr Wong is a public health specialist. He is currently an Independent Director of RHT Health Trust (listed on the SGX-ST). He was previously the Executive Director and Group CEO

of Cordlife Group Limited (listed on the SGX-ST), President of Thomson International and Executive Director of TMC Life Sciences Berhad (listed on the Bursa Malaysia). He was also the CEO and Executive Director of Hospital Division, Pantai Holdings Berhad. He is an elected Council Member of the Singapore Medical Association and was its President from 2006 to 2009. He is also an elected council member and Scribe of the Academy Medicine Singapore (AMS). He has held senior positions in the public sector, including Chief Operating Officer of Singapore General Hospital and Changi General Hospital and is also a part-time Senior Consultant with the Ministry of Health, Singapore. Dr Wong holds a MBBS and Masters of Medicine (Public Health) from the National University of Singapore and Masters of Business Administration (Finance) from the University of Leicester.

On 30 December 2019, the Board announced the appointment Dr Wong Chiang Yin as Group Chief Executive Officer and Executive Director of the Issuer. The appointment will take with effect from 1 February 2020.

### **Striking off of dormant subsidiaries**

As announced on 21 November 2019, four indirect subsidiaries incorporated in Malaysia in which the Issuer has an effective 100% interest, namely VB1 Property Sdn Bhd, VB3 Property Sdn Bhd, VB4 Property Sdn Bhd and VB5 Property Sdn Bhd, have been struck off pursuant to Section 550 of the Malaysian Companies Act, 2016. These subsidiaries have been dormant since incorporation.

The striking off of these dormant subsidiaries is not expected to have any material impact on the earnings per share and net tangible assets of the Group for the financial year ending 30 June 2020.

### **Change of Financial Year End from 31 December to 30 June**

As announced on 27 September 2019, the Issuer's financial year end shall be changed from 31 December to 30 June. Henceforth, the financial year of the Issuer will end on 30 June of each year. With the change of financial year, the next set of audited financial statements for the financial period ending 30 June 2020 will cover a period of 18 months from 1 January 2019 to 30 June 2020.

The Board of Directors' decision to change the financial year end was arrived at after taking into consideration the reporting requirements of the Issuer's subsidiaries in Singapore and Malaysia and management recommendations that the change would improve the Issuer's internal processes which will result in administrative and operational efficiencies.

Pursuant to Rules 705(1) and 705(2) of the Listing Manual of the SGX-ST, the Issuer intends to release the announcements of its financial results for the financial period commencing from 1 January 2019 to 30 June 2020 by the latest dates for release as set out in the table below:

<b>Financial Period covered</b>	<b>Comparative financial period covered</b>	<b>Type of announcement</b>	<b>Latest date of release</b>
1 October 2019 to 31 December 2019 (3 months period)	1 October 2018 to 31 December 2018 (3 months period)	Fourth quarter results	14 February 2020
1 January 2020 to 31 March 2020 (3 months period)	1 January 2019 to 31 March 2019 (3 months period)	Fifth quarter results	15 May 2020

1 January 2019 to 30 June 2020 (18 months period)	1 January 2018 to 30 June 2019 (18 months period)	Full year results (18 months)	29 August 2020
---	---	-------------------------------	----------------

In accordance with Rule 707(1) of the SGX-ST and the Companies Act, the Issuer will hold its next Annual General Meeting for the financial period from 1 January 2019 to 30 June 2020 on or before 31 October 2020."

9. The references to "Mr Quek Hong Sheng Roy" under paragraph 1 of the section "Information on Directors" of Appendix I appearing on page 177 shall be deleted in its entirety.